Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign up Log in
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 5 search results for "Augtyro" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
NSCLC Targeted Therapy: 8 Facts
... Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro ...
NSCLC Targeted Therapy: 8 Facts
... Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... dacomitinib (Vizimpro), erlotinib, gefitinib (Iressa), lazertinib (Lazcluze), and osimertinib (Tagrisso) ALK inhibitors, such as alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... dacomitinib (Vizimpro), erlotinib, gefitinib (Iressa), lazertinib (Lazcluze), and osimertinib (Tagrisso) ALK inhibitors, such as alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro ...
Biomarkers for Lung Cancer: 12 Things To Know
... good news is that several FDA-approved treatments now target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro ...
Biomarkers for Lung Cancer: 12 Things To Know
... good news is that several FDA-approved treatments now target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib (Augtyro ...
How Does Targeted Therapy for Lung Cancer Work?
... These drugs include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) Another ROS1 inhibitor, taletrectinib, is being studied in clinical trials.KRASKRAS mutations occur in up to 30 percent of NSCLC cases. One specific mutation, KRAS G12C, is found in 40 percent of those. ...
How Does Targeted Therapy for Lung Cancer Work?
... These drugs include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) Another ROS1 inhibitor, taletrectinib, is being studied in clinical trials.KRASKRAS mutations occur in up to 30 percent of NSCLC cases. One specific mutation, KRAS G12C, is found in 40 percent of those. ...
Lung Cancer Treatment Options
... It’s usually seen in people with NSCLC who do not have EGFR, ALK, or KRAS mutations.Medications that target the ROS1 gene rearrangement include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) NTRK InhibitorsIn a small number of NSCLC cases, there are mutations in one of the NTRK genes that cause ...
Lung Cancer Treatment Options
... It’s usually seen in people with NSCLC who do not have EGFR, ALK, or KRAS mutations.Medications that target the ROS1 gene rearrangement include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) NTRK InhibitorsIn a small number of NSCLC cases, there are mutations in one of the NTRK genes that cause ...